Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources. In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others. In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”. In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential. In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.